Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Protagonist Therapeutics Inc (NQ: PTGX ) 46.76 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Protagonist Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million October 29, 2024 Via ACCESSWIRE Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines September 10, 2024 Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. Via Benzinga Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 September 03, 2024 Via ACCESSWIRE PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024 August 06, 2024 PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. Via InvestorPlace Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 06, 2024 Via ACCESSWIRE Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update May 07, 2024 Via ACCESSWIRE Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data March 26, 2024 Via ACCESSWIRE Protagonist Therapeutics to Participate in Upcoming Investor Conferences March 06, 2024 Via ACCESSWIRE RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports August 01, 2024 Via ACCESSWIRE Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor July 31, 2024 Via ACCESSWIRE ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? July 28, 2024 Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% Via Benzinga AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday July 24, 2024 Via Benzinga Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update February 27, 2024 Via ACCESSWIRE Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 July 22, 2024 Via ACCESSWIRE 3 Growth Stocks No One Is Watching (But They Should Be) July 11, 2024 While overlooked growth stocks present high risks, it’s difficult to find any other sector with as much upside potential. Via InvestorPlace Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 June 28, 2024 Protagonist Therapeutics will join the SmallCap 600 on Wednesday. Via Investor's Business Daily Topics Stocks Exposures US Equities Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control June 13, 2024 Via ACCESSWIRE The 3 Best Biotech Stocks to Buy in June 2024 June 05, 2024 Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia. Via InvestorPlace Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 May 31, 2024 Via ACCESSWIRE Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress May 14, 2024 Via ACCESSWIRE PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event May 07, 2024 Via ACCESSWIRE Turnstone Biologics Appoints William Waddill to its Board of Directors April 16, 2024 From Turnstone Biologics Corp. Via GlobeNewswire Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda March 18, 2024 Via ACCESSWIRE Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year March 11, 2024 Via ACCESSWIRE New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera February 21, 2024 Via ACCESSWIRE Protagonist Therapeutics Reports Granting of Inducement Awards February 20, 2024 Via ACCESSWIRE New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study February 07, 2024 Via ACCESSWIRE Why Is Japanese Drugmaker Takeda Stock Trading Lower Today? February 01, 2024 Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated. Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session January 31, 2024 Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
